Author： Ouellet Daniele
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.9, Iss.2, 2010-03, pp. : 289-300
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer
Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. :
Access to resources
Recommend
A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
By Cahill Kate Stead Lindsay Lancaster Tim
Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. :
Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia
Drug Safety, Vol. 26, Iss. 9, 2003-01 ,pp. :
Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis
By Cranney Ann
Drug Safety, Vol. 28, Iss. 8, 2005-01 ,pp. :
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :